Multinational device leaders face compounding cost and technology pressures —
Maxima's engineering and manufacturing capabilities close that gap.

Maxima is a medical-device contract development and manufacturing organization (CDMO), not a single-product supplier. Four deliverables: ① Quality system (QMS auditable by the customer) ② Supplier management (evaluation, change control, traceability) ③ Medical-device lifecycle management (design input to post-market surveillance) ④ Systems integration (packing energy, control and sterilization routes into a smaller system). Plus one thing we do for ourselves: the four-gate capability and output (see section 06).

An ISO 13485 quality management system is in place and auditable by customers; by end-2026 we will undergo EU MDR QMS audit, with Maxima as the auditee. A signed ISO 13485 quality agreement with a strategic manufacturing partner, covering energy devices — exactly the core evidence MDR requires for "outsourced manufacturing and critical-supplier control", and the hardest document to prepare in the three-month readiness window.
What it means to the customer: no need to start from "does this factory have a QMS" — you can go straight to the substance of supplier-quality audit.

Over 30 precision-machining and semiconductor suppliers are already integrated; supplier evaluation, incoming inspection, change control and product traceability are daily-running processes, not documents backfilled for an order.
What it means to the customer: the supply chain is within tens of kilometers, so change and audit can be done round-trip in a day.

From design input, risk management, design verification, regulatory submission, post-market surveillance (PMS) to change and recall management, the full lifecycle sits under one QMS, not outsourced in segments. Track record: Taiwan TFDA approved for market; Gen 2 (MAXXONIC) US 510(k) K263177 filed on 2026-09-11, final decision estimated 2026-12-10; the 510(k) is submitted and held by Maxima, and the supply entity is also Maxima — single point of accountability, no shuttling between customer and contractor.
What it means to the customer: the regulatory, manufacturing and audited entities are the same, so due diligence can be done in one pass.

Each technology module is modular and menu-based: transducer, power and energy management, control algorithms, sterilization route, blade and clamp-force configurations are each independent modules with their own verification evidence; the customer gives a spec, we select and combine from existing modules, adding only the necessary new modules — no development from scratch, and the verification scope is therefore definable.
We also build a public-domain protection umbrella: we inventory expired public-domain technologies item by item into a verifiable list — of the de-duplicated 276 patent-family members, 96 US patents have expired and are freely practicable — and choose design paths accordingly, placing the product on a foundation no one can exclusively own, reducing the space for competitors to abuse patents and disrupt the customer's market-entry timeline with litigation.

The four gates Maxima walked through itself are now a service deliverable for external clients. For any medical-device product spec a client proposes, we can re-run the same process for that spec and deliver the same form of output: G1 patent screening — verify patent risk country by country for the specified item, producing an auditable record book; G2 regulatory map — map the access path, documents and timeline for each market against that spec; G3 economic viability — assessed against public market prices, not our cost, and without disclosing our cost structure; G4 channel accessibility — assess the terminal-channel form and collaboration model for that spec.

Taiwan's advantage is not wages, but three verifiable things:
① Prices diverge. Same hospital, same type of device — the NHI self-pay price-comparison website shows hospital charges: Medtronic Sonicision 7 NT$49,650, J&J ACE+7 NT$34,500, Maxima NT$31,950 (all China Medical University Hospital) — same-hospital same-type gap NT$17,700, about 36% (1.55×). The hospital thus gains one more option to negotiate — that is the mechanism of "driving the majors to lower prices".
② Commercialization gets done. The world's second commercialized cordless ultrasonic scalpel system — we built it in 3 years (Gen 1 shipped in Taiwan in 2022) — not a prototype, but made manufacturable, certifiable and shippable.
③ Redesign is fast. From straight to curved jaw, we took 4 years (2022 Gen 1 straight jaw in Taiwan → 2026 Gen 1.5 self-developed curved-jaw clamp-force module cleared): design, supply chain, regulation and mass production are on the same island, so clinical feedback to design spec has no time lag — no cross-time-zone round trips or waiting for samples to ship.